Cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) reactivation after transplantation put patients at an increased risk of graft rejection mainly among those who receive organs that are positive in their donor biopsies. The aim of this study was to investigate the presence of CMV and HHV-6 DNA in liver biopsy specimens from the donors and from their grafts for correlation with rejection after transplantation. We followed 41 liver transplantation patients whose samples were evaluated using nested-polymerase chain reactions (N-PCR). Twenty-one (51%) of the 41 studied patients experienced rejection; 4/21 (19%) were CMV positive in the donor biopsy specimens and remained positive; another 5 subjects became positive. The patients who received organs from donors with biopsies positive for CMV demonstrated a trend to develop graft rejection after transplantation (Fisher's exact test [P ϭ .0591] with significant results on univariate and multivariate analysis [P ϭ .042]). Eight of the 21 who experienced rejection episodes were HHV-6 positive in the donor biopsy but there was no statistical significance CMV DNA diagnosed in liver donor biopsies remained positive posttransplantation in liver biopsy recipients; it was considered a tendency to develop acute cellular rejection after transplantation.
H
ERPESVIRUS reactivation is common after liver transplantation. A seropositive donor coupled with a seronegative recipient is a risk factor for primary cytomegalovirus (CMV) infection. Secondary infection by reactivation or superinfection may also lead to CMV disease during immunosuppression. Among recipients who receive immunosuppressive medications there is a seroprevalence of human herpesvirus-6 (HHV-6), which reactivates from latency posttransplantation, often together with CMV infection. 1 CMV and HHV-6 establish latent infections for the lifetime of the host with possible reactivation later.
2 Among the factors associated with virus reactivation after liver transplantation is acute allograft rejection. 3, 4 Our study analyzed the presence of CMV and HHV-6 DNA in donor liver biopsy specimens correlated with rejection episodes after transplantation.
PATIENTS AND METHODS
Herpesvirus was studied prospectively in 41 liver transplantation patients from 2005 to 2007 in an epidemiological, observational, analytic, longitudinal cohort prospective study. Recipient monitoring started at the moment of surgery. The first liver biopsy specimen was collected at the bench from the organ before transplantation (pretransplantation graft biopsy). Other liver biopsy specimens (posttransplantation) were collected when clinically indicated due to elevated liver enzyme levels. Among 145 biopsy specimens: 41 were from the donor and 104 from the graft. We analyzed the biopsy specimens using nested-polymerase chain reaction (N-PCR) for CMV and HHV-6 DNA as well as monitored the recipients for cellular rejection. The diagnostic and clinical monitoring of graft function for acute rejection episodes were evaluated according to the Banff International Consensus. 5 All acute rejection episodes were treated with methylprednisolone according to our protocol. All patients from this study received prophylaxis for Herpes simplex infection. 6 All recipients were positive for CMV immunoglobulin G (IgG) before transplantation; no recipient showed positive serology for HHV-6 before transplantation. All donors were CMV positive serologically. All patients underwent our previously published protocol for immunosuppression. 6 
Molecular Tissue Testing
Viral DNA was extracted from liver biopsy specimens using the Quiagen Dneasy Tissue Kit (Uniscience, São Paulo, Brazil) according to the manufacturer's instructions with some modifications to achieve final elution volumes of 30 L.
6
CMV and HHV-6 N-PCR Amplification Five microliters of extracted DNA were used for the N-PCR for CMV and HHV-6 using a mixture containing specific primers (CMV primers; Invitrogen, São Paulo, Brazil), using the a previously described technique 7 with some modifications. Specific primers for HHV-6 (HHV-6 primers; Invitrogen) were applied with the technique previously described by Secchiero et al 8 with some modifications. The amplifications were performed in a Peltier Thermal Cycler (MJ Research, Waltham, Mass, United States). The N-PCR products were analyzed under UV light after electrophoresis in agarose gels (Gibco-BRL Life Technology, Carlsbad, California, United States) in tetramethylbenzidine buffer after staining with ethidium bromide. All primer sequences and PCR products were analyzed using the Genbank database before initiating the study. PCR using primers for beta-globin gene amplification, which were performed on samples to detect possible false-negative results, were not included in this study.
Statistical Analysis
The results were compared with chi-square and Fisher exact test and when necessary with univariate or multivariate logistic analyses. For all tests, P Ͻ .05 was considered statistically significant. This study was approved by our Institutional Ethics Committee (number 030/2006).
RESULTS
Twenty-one (51%) of 41 studied patients showed positive histopathology for liver rejection; 4/21 (19%) were positive for CMV in the pretransplantation graft biopsy and remained positive, whereas another 5 became positive on posttransplant graft biopsies ( Table 1 ). The patients who displayed a pretransplantation graft biopsy positive for CMV DNA show significant results (P ϭ .042) upon univariate or multivariate analysis (Table 2) , as well as in Fisher exact test (Table 3) , with a tendency toward development of graft rejection after transplantation (P ϭ .0591). Eight of the 21 who were positive for HHV-6 on pretransplantation graft biopsies had rejection but it was not significant. The other patients who did not have rejection and were positive for herpesvirus are described in Tables 3  and 4 .
DISCUSSION
The beta-herpesviruses are common viral pathogens that influence the outcomes of liver transplantation. Their effects are associated with an increased predisposition to rejection reducing allograft survival. Fifty-one percent of patients in this study developed graft rejection and 71% displayed herpesvirus infection. Allograft rejection is the most potent inducer of CMV reactivation, and thus is considered a significant risk factor for CMV disease after liver transplantation. A few previous studies 4,9,10 have reported an association between HHV-6 and allograft dysfunction or rejection.
A recent study showed CMV positivity (CMV-IgG) among 94.7% of patients before transplantation, hence there is some importance of serological investigations and diagnostic examinations before transplantation.
11 CMV-seronegative recipients of liver allografts from CMV-seropositive donors (CMVDϩ/RϪ) are at the highest risk of CMV disease and its complications. 12 In our analysis the patients who displayed positive CMV DNA in pretransplantation graft biopsies were significantly more likely to develop rejection episodes after transplantation (Table 2) .
Almost all patients who had CMV DNA in the donor biopsy remained positive after transplantation and had rejection. After transplantation 14 recipients were positive for CMV DNA, 9 had rejection as shown in Razonable et al demonstrated a significant association between acute rejection and delayed-onset CMV disease in liver transplant recipients. CMV disease caused significant morbidity and reduced allograft survival. 4, 9, 13 Of 21 recipients who experienced rejection, HHV-6 DNA was observed in 8 pretransplantation graft biopsy specimens and 6/8 remained positive after transplantation; another 6 became positive after transplantation. Although HHV-6 showed a higher positivity than CMV, we failed to observe a significant relation although other studies have suggested that HHV-6 causes dysfunction that can lead to rejection after transplantation.
2,14
In summary CMV DNA diagnosed in pretransplantation graft biopsy specimens remained positive posttransplantation on graft biopsies. This common complication negatively influences liver transplantation outcomes and is a risk factor to develop acute cellular rejection episodes. 
